D. E. Shaw & Co. Inc. lifted its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 9.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 833,943 shares of the biopharmaceutical company's stock after purchasing an additional 69,178 shares during the quarter. D. E. Shaw & Co. Inc. owned 1.70% of Theravance Biopharma worth $7,847,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Invesco Ltd. boosted its stake in Theravance Biopharma by 3.5% in the fourth quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock valued at $433,000 after buying an additional 1,576 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after acquiring an additional 2,060 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Theravance Biopharma during the fourth quarter worth about $25,000. SG Americas Securities LLC raised its position in shares of Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock worth $181,000 after acquiring an additional 3,349 shares during the last quarter. Finally, Martingale Asset Management L P raised its position in shares of Theravance Biopharma by 7.7% during the fourth quarter. Martingale Asset Management L P now owns 58,650 shares of the biopharmaceutical company's stock worth $552,000 after acquiring an additional 4,200 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Tuesday, February 25th. StockNews.com upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $11.33.
Read Our Latest Research Report on TBPH
Theravance Biopharma Stock Up 2.1%
Shares of NASDAQ:TBPH traded up $0.19 during midday trading on Monday, reaching $9.39. 292,754 shares of the company traded hands, compared to its average volume of 273,408. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $10.90. The firm has a market capitalization of $469.51 million, a price-to-earnings ratio of -9.30 and a beta of -0.10. The firm's fifty day moving average price is $9.16 and its two-hundred day moving average price is $9.31.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.
Insider Activity
In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares in the company, valued at approximately $3,330,342. This trade represents a 1.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.90% of the company's stock.
Theravance Biopharma Company Profile
(
Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Featured Articles
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
